FocalTherics Files for Public Offering, Dilution Risk Hits Shares
FOCL has more than doubled off its 52-week low of $1.26.
Summary
FocalTherics (EDAP TMS SA) announced a proposed public offering of American Depositary Shares, with no size or pricing disclosed. The offering will dilute existing shareholders, and the lack of terms adds uncertainty. The stock closed at $6.01, giving a market cap of about $228 million — even a modest raise could be material. This follows a June partnership with MellingMedical and the launch of its first commercial Focal One program for endometriosis, so the capital raise may fund commercialization. Watch for the pricing and size of the offering, which will determine the dilution impact.
At the time of this announcement, FOCL was trading at $6.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $227.9M. The 52-week trading range was $1.26 to $6.40. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.